728 related articles for article (PubMed ID: 31228622)
1. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
2. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
[TBL] [Abstract][Full Text] [Related]
3. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
5. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
[TBL] [Abstract][Full Text] [Related]
6. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
7. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
[TBL] [Abstract][Full Text] [Related]
8. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
9. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
10. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
11. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
13. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
[TBL] [Abstract][Full Text] [Related]
14. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
15. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
17. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; Saigi M; Alameda D; Gomez-Mariano G; Martinez-Delgado B; Alburquerque-Bejar JJ; Carretero J; Tonda R; Esteve-Codina A; Catala I; Palmero R; Jove M; Lazaro C; Patiño-Garcia A; Gil-Bazo I; Verdura S; Teulé A; Torres-Lanzas J; Sidransky D; Reguart N; Pio R; Juan-Vidal O; Nadal E; Felip E; Montuenga LM; Sanchez-Cespedes M
Ann Oncol; 2020 Feb; 31(2):274-282. PubMed ID: 31959344
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
[TBL] [Abstract][Full Text] [Related]
20. Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation.
Huang J; Zhang SL; Zhang C; Huang W; Zhang Z; Chen YQ; Su JW; Yan HH; Chen HJ; Yang JJ; Wang J; Wu YL
Clin Transl Med; 2024 May; 14(5):e1683. PubMed ID: 38736106
[No Abstract] [Full Text] [Related]
[Next] [New Search]
